Mallinckrodt grows investment in Dublin College Business and Technology Park Site to €85 million
Creates 40 R&D jobs and grows total to 120 new roles at new site.
Mallinckrodt has officially opened its new offices in College Business and Technology Park in Blanchardstown, Dublin, and announcing creation of a new €10 million state-of-the-art R&D facility at the location. The R&D facility will house global device engineering for the company and bring 40 more new jobs to the site, bringing the overall total of new positions there to 120 by 2017. With its May 2015 announcement and this commitment, Mallinckrodt’s total investment in the site has grown to €85 million. This project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
Mallinckrodt has a long history of operations in Ireland and has had a presence there for over 20 years. Its new offices at the College Business and Technology Park, Blanchardstown was dedicated this morning by Minister for Social Protection, Leo Varadkar TD, and Mallinckrodt President and CEO, Mark Trudeau.
Commenting, Leo Varadkar, local TD and Minister for Social Protection, said: "I’m delighted to announce this new investment by Mallinckrodt in Blanchardstown. This company is at the cutting edge of new and innovative treatments and the range of facilities being developed here is an exciting development. The Government has worked hard to create the right conditions for cutting edge Pharma and BioPharma companies to locate in Ireland and the provision of high quality jobs in this new Research and Development facility is very welcome. The number of people at work is back up to 2 million and unemployment continues to fall. This investment means more jobs and more quality jobs in our community.”
Commenting, Mark Trudeau said: “Today’s dedication and announcement reaffirms Ireland’s strategic importance to Mallinckrodt as we continue with our transition to become a high-growth, global specialty pharmaceutical business. We are in the process of bringing global R&D activities for medical devices to this location and the team will focus on developing systems for delivery of certain specialty pharmaceutical therapies in our portfolio.
Over more than two decades, our Irish colleagues have been a significant asset to our business. We are now entering a new and exciting era for Mallinckrodt in Ireland, which will continue to play an important role in the development of our global business.”
Commenting, Martin Shanahan, Chief Executive of IDA Ireland, said: “The biopharma industry is one of the fastest growing sectors in Ireland. Ireland is a leading location for the manufacture and development of biopharmaceutical medicines in the world. In 2015, the sector employed over 25,000 people in Ireland and has accounted for over €30bn in exports. Biopharma companies like Mallinckrodt are currently developing and manufacturing these “next generation” of medicines from their base here in Dublin. I wish Mark and the Mallinckrodt team every success as they continue to grow their operations in Ireland.”
Welcoming today’s announcement, Dr David Keenan, Vice President, Global External Supply and Managing Director, Mallinckrodt Pharmaceuticals, Ireland, said, “Building this R&D facility focused on global device development significantly adds to the importance and range of operations that will take place at our new College Business and Technology Park site. Our new corporate offices are now complete and teams are moving in. Construction continues on our new manufacturing facility, and fit-out and commissioning processes are underway. The new jobs being created offer a diverse range of skilled roles in research, product development, manufacturing and commercial support functions.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance